Association of KDR (rs2071559, rs1870377), CFH (rs1061170, rs1410996) genes variants and serum levels with pituitary adenoma.
CFH
KDR
hormonal activity
invasiveness
pituitary adenoma
recurrence
rs1061170
rs1410996
rs1870377
rs2071559
serum levels
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
revised:
09
09
2023
received:
24
05
2023
accepted:
19
09
2023
pubmed:
7
10
2023
medline:
7
10
2023
entrez:
7
10
2023
Statut:
aheadofprint
Résumé
Pituitary adenomas (PA) are slow-growing, benign tumors that usually do not metastasize to other body organs. Although they are referred to as benign, tumor growth can eventually put pressure on nearby structures, spread to surrounding tissues, and cause symptoms. The exact cause of PA is unknown, and the pathogenesis is multifactorial. Our study included PA patients and healthy volunteers. Genomic DNA was extracted using the DNA salting-out method. All participants were genotyped for the KDR rs2071559, rs1870377, CFH rs1061170, and rs1410996 polymorphisms. Serum levels of KDR and CFH were examined using the ELISA method. The results of the present study showed that KDR rs2071559 A allele was associated with the occurrence of PA, hormonally active PA, invasive PA, and PA without recurrence development. KDR rs1870377 increased the probability of invasive PA and PA recurrence. CFH rs1061170 C allele was associated with hormonally active PA and the T allele was associated with non-invasive PA development. KDR rs2071559, rs1870377, and CFH rs1061170 could be potential biomarkers associated with PA.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2289Subventions
Organisme : Research Council of Lithuania
ID : S-SV-22-79
Informations de copyright
© 2023 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
Afshar-Kharghan, V. (2017). The role of the complement system in cancer. The Journal of Clinical Investigation, 127(3), 780-789. https://doi.org/10.1172/JCI90962
Al Awaida, W., Ahmed, A. A., Hamza, A. A., Amber, K. I., Al-Ameer, H. J., Jarrar, Y., Fatima, G., Maslat, A. O., Gushchina, Y., Al Bawareed, O., & Hadi, N. R. (2021). Association of KDR rs1870377 genotype with clopidogrel resistance in patients with post percutaneous coronary intervention. Heliyon, 7(2), e06251. https://doi.org/10.1016/j.heliyon.2021.e06251
Alwi, Z. B. (2005). The use of SNPs in pharmacogenomics studies. The Malaysian Journal of Medical Sciences: MJMS, 12(2), 4-12.
Appelboom, G., Piazza, M., Hwang, B. Y., Bruce, S., Smith, S., Bratt, A., Bagiella, E., Badjatia, N., Mayer, S., & Sander Connolly, E. (2011). Complement factor H Y402H polymorphism is associated with an increased risk of mortality after intracerebral hemorrhage. Journal of Clinical Neuroscience, 18(11), 1439-1443. https://doi.org/10.1016/j.jocn.2011.04.001
Armento, A., Schmidt, T. L., Sonntag, I., Merle, D. A., Jarboui, M. A., Kilger, E., Clark, S. J., & Ueffing, M. (2021). CFH loss in human RPE cells leads to inflammation and complement system dysregulation via the NF-κB pathway. International Journal of Molecular Sciences, 22(16), 8727. https://doi.org/10.3390/ijms22168727
Bakhtiari, S., Sulaimany, S., Talebi, M., & Kalhor, K. (2020). Computational prediction of probable single nucleotide polymorphism-cancer relationships. Cancer Informatics, 19, 1176935120942216. https://doi.org/10.1177/1176935120942216
Cho, H. Y., Park, H. S., Ko, E. J., Ryu, C. S., Kim, J. O., Kim, Y. R., Ahn, E. H., Lee, W. S., & Kim, N. K. (2019). Association of complement factor D and H Polymorphisms with recurrent pregnancy loss. International Journal of Molecular Sciences, 21(1), 17. https://doi.org/10.3390/ijms21010017
Daly, A. F., & Beckers, A. (2020). The epidemiology of pituitary adenomas. Endocrinology and Metabolism Clinics of North America, 49(3), 347-355. https://doi.org/10.1016/j.ecl.2020.04.002
Deng, N., Zhou, H., Fan, H., & Yuan, Y. (2017). Single nucleotide polymorphisms and cancer susceptibility. Oncotarget, 8(66), 110635-110649. https://doi.org/10.18632/oncotarget.22372
Ezzeldin, N., El-Lebedy, D., Darwish, A., El-Bastawissy, A., & Shalaby, A. E. (2015). Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer. Contemporary Oncology = Współczesna Onkologia, 19(6), 441-445. https://doi.org/10.5114/wo.2015.56202
Farrell, W. E., & Clayton, R. N. (2000). Molecular pathogenesis of pituitary tumors. Frontiers in Neuroendocrinology, 21(3), 174-198.
Fraga, A., Ribeiro, R., Coelho, A., Vizcainom, J. R., Coutinh, H., Lopes, J. M., Principe, P., Lobato, C., Lopes, C., & Medeiros, R. (2017). Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. BMC Urology, 17, 12. https://doi.org/10.1186/s12894-017-0201-y
Francis, K., Lewis, B. M., Akatsu, H., Monk, P. N., Cain, S. A., Scanlon, M. F., Morgan, B. P., Ham, J., & Gasque, P. (2003). Complement C3a receptors in the pituitary gland: A novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. The FASEB Journal, 17(15), 2266-2268. https://doi.org/10.1096/fj.02-1103fje
Fu, Y., Sun, W., Xu, C., Gu, S., Li, Y., Liu, Z., & Chen, J. (2014). Genetic variants in KDR transcriptional regulatory region affect promoter activity and intramuscular fat deposition in Erhualian pigs. Animal Genetics, 45(3), 373-380. https://doi.org/10.1111/age.12148
Gao, Y., Ma, P., He, Y., Liu, Y., & Jiang, Y. (2016). Genetic variations of kinase inserts domain receptor (KDR) Gene are associated with the risk of Astrocytomas. Molecular Neurobiology, 53(4), 2541-2549. https://doi.org/10.1007/s12035-015-9239-6
Glebauskiene, B., Vilkeviciute, A., Liutkeviciene, R., Jakstiene, S., Kriauciuniene, L., Zemaitiene, R., & Zaliuniene, D. (2017). Association of FGFR2 rs2981582, SIRT1 rs12778366, STAT3 rs744166 gene polymorphisms with pituitary adenoma. Oncology Letters, 13(5), 3087-3099. https://doi.org/10.3892/ol.2017.5840
Greten, F. R., & Grivennikov, S. I. (2019). Inflammation and cancer: Triggers, mechanismns, and consequences. Immunity, 51(1), 27-41. https://doi.org/10.1006/j.immuni.2019.06.025
He, G., & Karin, M. (2011). NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Research, 21(1), 159-168.
Ho, K., Fleseriu, M., Kaiser, U., Salvatori, R., Brue, T., Lopes, M. B., Kunz, P., Molitch, M., Camper, S. A., Gadelha, M., Syro, L. V., Laws, E., Reincke, M., Nishioka, H., Grossman, A., Barkan, A., Casanueva, F., Wass, J., Mamelak, A., … Melmed, S. (2021). Pituitary neoplasm nomenclature workshop: Does adenoma stand the test of time? Journal of the Endocrine Society, 5(3). https://doi.org/10.1210/jendso/bvaa205
Holmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007). Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling, 19(10), 2003-2012. https://doi.org/10.1016/j.cellsig.2007.05.013
Hu, K., Xie, X., Wang, R., Wu, F., & Zhang, Y. (2017). Association of the rs2071559 (T/C) polymorphism with lymphatic metastasis in patients with nasopharyngeal carcinoma. Oncology Letters, 14(6), 7681-7686. https://doi.org/10.3892/ol.2017.7209
Jaffrain-Rea, M. L., Daly, A. F., Angelini, M., Petrossians, P., Bours, V., & Beckers, A. (2011). Genetic susceptibility in pituitary adenomas: From pathogenesis to clinical implications. Expert Review of Endocrinology and Metabolism, 6(2), 195-214. https://doi.org/10.1586/eem.10.87
Javanbakht, A., D'Apuzzo, M., Badie, B., & Salehian, B. (2018). Pituitary metastasis: A rare condition. Endocrine Connections, 7(10), 1049-1057. https://doi.org/10.1530/EC-18-0338
Jinnin, M., Medici, D., Park, L., Limaye, N., Liu, Y., Boscolo, E., Bischoff, J., Vikkula, M., Boye, E., & Olsen, B. R. (2008). Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nature Medicine, 14(11), 1236-1246. https://doi.org/10.1038/nm.1877
Kaira, K., Imai, H., Kawasaki, T., Hashimoto, K., Miura, Y., Shiono, A., Yamaguchi, O., Mouri, A., Kobayashi, K., Yasuda, M., & Kagamu, H. (2022). Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC. Oncology Reports, 48(6), 214. https://doi.org/10.3892/or.2022.8429
Kardys, I., de Maat, M. P., Klaver, C. C., Despriet, D. D., Uitterlinden, A. G., Hofman, A., de Jong, P. T., & Witteman, J. C. (2007). Usefulness of combining complement factor H and C-reactive protein genetic profiles for predicting myocardial infarction (from the Rotterdam Study). The American Journal of Cardiology, 100(4), 646-648. https://doi.org/10.1016/j.amjcard.2007.03.079
Ken, H. O., Fleseriu, M., Kaiser, U., Salvatori, R., Brue, T., Lopes, M. B., Kunz, P., Molitch, M., Camper, S. A., Gadelha, M., Syro, L. V., Laws, E., Reincke, M., Nishioka, H., Grossman, A., Barkan, A., Casanueva, F., Wass, J., Mamelak, A., … Melmed, S. (2021). Pituitary neoplasm nomenclature workshop: Does adenoma stand the test of time? Journal of the Endocrine Society, 5(3), bvaa205. https://doi.org/10.1210/jendso/bvaa205
Kopp, A., Hebecker, M., Svobodová, E., & Józsi, M. (2012). Factor H: A complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules, 2(1), 46-75. https://doi.org/10.3390/biom2010046
Lake, M. G., Linda, S. K., & Samya, V. C. (2013). Pituitary adenomas: An overview. American Family Physician, 88, 319-327.
Larkin, S., & Ansorge, O. (2000). Pathology and pathogenesis of pituitary adenomas and other sellar lesions. In K. R. Feingold, B. Anawalt, M. R. Blackman, A. Boyce, G. Chrousos, E. Corpas, W. W. de Herder, K. Dhatariya, K. Dungan, J. Hofland, S. Kalra, G. Kaltsas, N. Kapoor, C. Koch, P. Kopp, M. Korbonits, C. S. Kovacs, W. Kuohung, B. Laferrère, et al. (Eds.), Endotext. MDText.com, Inc.
Laskowski, J., Renner, B., Pickering, M. C., Serkova, N. J., Smith-Jones, P. M., Clambey, E. T., Nemenoff, R. A., & Thurman, J. M. (2020). Complement factor H-deficient mice develop spontaneous hepatic tumors. The Journal of Clinical Investigation, 130(8), 4039-4054. https://doi.org/10.1172/JCI135105
Lazzeri, S., Orlandi, P., Figus, M., Fioravanti, A., Cascio, E., Di Desidero, T., Agosta, E., Canu, B., Sartini, M. S., Danesi, R., Nardi, M., & Bocci, G. (2012). The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. ScientificWorldJournal, 2012, 420190. https://doi.org/10.1100/2012/420190
Li, J., Long, D., Wu, S., Wu, X., Wei, B., Chen, D., Shao, Y., Wang, H., Cui, L., Chen, X., & Yu, L. (2020). Association of CFH polymorphism with susceptibility to sepsis caused by Pseudomonas aeruginosa in Chinese Han populations: A multi-center study. Gene, 722, 144127. https://doi.org/10.1016/j.gene.2019.144127
Maugeri, A., Barchitta, M., & Agodi, A. (2019). The association between complement factor H rs1061170 polymorphism and age-related macular degeneration: A comprehensive meta-analysis stratified by stage of disease and ethnicity. Acta Ophthalmologica, 97(1), e8-e21. https://doi.org/10.1111/aos.13849
Mehta, G. U., & Lonser, R. R. (2017). Management of hormone-secreting pituitary adenomas. Neuro-Oncology, 19(6), 762-773. https://doi.org/10.1093/neuonc/now130
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., Giustina, A., Wass, J. A. H., & Ho, K. K. Y. (2022). Clinical biology of the pituitary adenoma. Endocrine Reviews, 43(6), 1003-1037. https://doi.org/10.1210/endrev/bnac010
Meri, S., & Haapasalo, K. (2020). Function and dysfunction of complement factor H during formation of lipid-rich deposits. Frontiers in Immunology, 11, 611830. https://doi.org/10.3389/fimmu.2020.611830
Møller, M. W., Andersen, M. S., Glintborg, D., Pedersen, C. B., Halle, B., Kristensen, B. W., & Poulsen, F. R. (2019). Pituitary adenoma. Ugeskrift for Laeger, 181(20), V05180331.
Neto, J. M., Viturino, M. G., Ananina, G., Bajano, F. F., Costa, S. M. D. S., Roque, A. B., Borges, G. F., Franchi, R., Rim, P. H., Medina, F. M., Costa, F. F., Melo, M. B., & de Vasconcellos, J. P. (2021). Association of genetic variants rs641153 (CFB), rs2230199 (C3), and rs1410996 (CFH) with age-related macular degeneration in a Brazilian population. Experimental Biology and Medicine (Maywood, N.J.), 246(21), 2290-2296. https://doi.org/10.1177/15353702211024543
Pădureanu, V., Boldeanu, M. V., Streaţă, I., Cucu, M. G., Siloşi, I., Boldeanu, L., Bogdan, M., Enescu, A. Ş., Forţofoiu, M., Enescu, A., Dumitrescu, E. M., Alexandru, D., Şurlin, V. M., Forţofoiu, M. C., Petrescu, I. O., Petrescu, F., Ioana, M., Ciurea, M. E., & Săftoiu, A. (2017). Determination of VEGFR-2 (KDR) 604A>G polymorphism in pancreatic disorders. International Journal of Molecular Sciences, 18, 439.
Paradowska-Gorycka, A., Stypinska, B., Pawlik, A., Malinowski, D., Romanowska-Prochnicka, K., Manczak, M., & Olesinska, M. (2019). KDR (VEGFR2) genetic variants and serum levels in patients with rheumatoid arthritis. Biomolecules, 9(8), 355. https://doi.org/10.3390/biom9080355
Qian, Y., Ding, L., Cao, L., Yu, Z., Shao, X., Wang, L., Zhang, M., Wang, Q., Che, X., Jiang, N., Yan, H., Fang, W., Jin, Y., Huang, J., Gu, A., & Ni, Z. (2022). Gene polymorphisms of VEGF and KDR are associated with initial fast peritoneal solute transfer rate in peritoneal dialysis. BMC Nephrology, 23(1), 365. https://doi.org/10.1186/s12882-022-02975-5
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D. (2018). Complement in cancer: Untangling an intricate relationship. Nature Reviews. Immunology, 18(1), 5-18.
Russ, S., Anastasopoulou, C., & Shafiq, I. (2022). Pituitary adenoma. In StatPearls [Internet]. StatPearls Publishing.
Rydén, L., Linderholm, B., Nielsen, N. H., Emdin, S., Jönsson, P. E., & Landberg, G. (2003). Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Research and Treatment, 82(3), 147-154. https://doi.org/10.1023/B:BREA.0000004357.92232.cb
Salminen, A., Pietiäinen, M., Paju, S., Sorsa, T., Mäntylä, P., Buhlin, K., Sinisalo, J., & Pussinen, P. J. (2022). Common complement factor H polymorphisms are linked with periodontitis in elderly patients. Journal of Periodontology, 93(11), 1626-1634. https://doi.org/10.1002/JPER.22-0005
Shen, Y., Meri, S., & Yang, Y. (2003). Complement activation and regulation in neurodegenerative disease such as Alzheimer's disease. Progress in Neurobiology, 70, 463-472. https://doi.org/10.1016/j.pneurobio.2003.08.001
Shibuya, M. (2011). Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-Angiogenic therapies. Genes & Cancer, 2(12), 1097-1105. https://doi.org/10.1177/1947601911423031
Sidaraite, A., Liutkeviciene, R., Glebauskiene, B., Vilkeviciute, A., & Kriauciuniene, L. (2020). Associations of cholesteryl ester transfer protein (CETP) gene variants with pituitary adenoma. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic, 164(2), 189-195. https://doi.org/10.5507/bp.2019.016
Singh, N., Baby, D., Rajguru, J. P., Patil, P. B., Thakkannavar, S. S., & Pujari, V. B. (2019). Inflammation and cancer. Annals of African Medicine, 18(3), 121-126. https://doi.org/10.4103/aam.aam_56_18
Su, M. T., Lin, S. H., Lee, I. W., Chen, Y. C., & Kuo, P. L. (2011). Association of polymorphisms/haplotypes of the genes encoding vascular endothelial growth factor and its KDR receptor with recurrent pregnancy loss. Human Reproduction, 26(4), 758-764.
Suchankova, P., Henningsson, S., Baghaei, F., Rosmond, R., Holm, G., & Ekman, A. (2009). Genetic variability within the innate immune system influences personality traits in women. Genes, Brain, and Behavior, 8(2), 212-217. https://doi.org/10.1111/j.1601-183X.2008.00461.x
The AACR Project GENIE Consortium. (2017). AACR project GENIE: Powering precision medicine through an international consortium. Cancer Discovery, 7(8), 818-831. Dataset Version 8.
Trouillas, J., Jaffrain-Rea, M. L., Vasiljevic, A., Raverot, G., Roncaroli, F., & Villa, C. (2020). How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel), 12(2), 514. https://doi.org/10.3390/cancers12020514
Vandeva, S., Jaffrain-Rea, M. L., Daly, A. F., Tichomirowa, M., Zacharieva, S., & Beckers, A. (2010). The genetics of pituitary adenomas. Best Practice & Research. Clinical Endocrinology & Metabolism, 24(3), 461-476. https://doi.org/10.1016/j.beem.2010.03.001
Varlamov, E. V., McCartney, S., & Fleseriu, M. (2019). Functioning pituitary adenomas - current treatment options and emerging medical therapies. European Endocrinology, 15(1), 30-40. https://doi.org/10.17925/EE.2019.15.1.30
Vasconcelos, V. C. A., Lourenço, G. J., Brito, A. B. C., Vasconcelos, V. L., Maldaun, M. V. C., Tedeschi, H., Marie, S. K. N., Shinjo, S. M., & Lima, C. S. P. (2019). Associations of VEGFA and KDR single-nucleotide polymorphisms and increased risk and aggressiveness of high-grade gliomas. Tumor Biology, 41(9), 101042831987209. https://doi.org/10.1177/1010428319872092
Wang, Y., Zheng, Y., Zhang, W., Yu, H., Lou, K., Zhang, Y., Qin, Q., Zhao, B., Yang, Y., & Hui, R. (2007). Polymorphisms of KDR gene are associated with coronary heart disease. Journal of the American College of Cardiology, 50(8), 760-767. https://doi.org/10.1016/j.jacc.2007.04.074
Yang, Q., & Li, X. (2019). Molecular network basis of invasive pituitary adenoma: A review. Frontiers in Endocrinology, 10, 7. https://doi.org/10.3389/fendo.2019.00007
Yoon, Y. H., Hwang, H. J., Sung, H. J., Heo, S. H., Kim, D. S., Hong, S. H., & Cho, J. Y. (2019). Upregulation of complement factor H by SOCS-1/3(−)STAT4 in lung cancer. Cancers (Basel), 11, 471-486.
Zhang, D. F., Li, J., Wu, H., Cui, Y., Bi, R., Zhou, H. J., Wang, H. Z., Zhang, C., Wang, D., Alzheimer's Disease Neuroimaging Initiative (ADNI), Kong, Q. P., Li, T., Fang, Y., Jiang, T., & Yao, Y. G. (2016). CFH variants affect structural and functional brain changes and genetic risk of Alzheimer's disease. Neuropsychopharmacology, 41(4), 1034-1045. https://doi.org/10.1038/npp.2015.232
Zhang, S. D., McCrudden, C. M., Meng, C., Lin, Y., & Kwok, H. F. (2018). The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. Oncotargets and Therapy, 8, 835-843. https://doi.org/10.2147/OTT.S80518